Chardan Capital Markets Downgrades NeuBase Therapeutics (NBSE) to Neutral
FREE Breaking News Alerts from StreetInsider.com!
StreetInsider.com Top Tickers, 8/17/2026
- Wall Street indexes slip as oil prices rise, retail results awaited
- Trump threatens to bomb Oman over Iran stance
- Why this Wall Street strategist says the "trade is long gold"
- U.S. EV market shows signs of bottoming out: Bernstein
- Micron rises as White House presses Apple to avoid Chinese memory chips
- Wall Street indexes slip as oil prices rise, retail results awaited
- Oil settles up over $2 as Iran war stalemate stokes supply concerns
- Trump threatens to bomb Oman over Iran stance
- BofA sees Micron EPS topping $230 by FY30, calls peak fears overblown
- L3Harris CEO steps down amid conduct review, shares drop
RBC Capital Downgrades NeuBase Therapeutics (NBSE) to Sector Perform
October 18, 2022 5:23 AM EDTRBC Capital analyst Brian Abrahams downgraded NeuBase Therapeutics (NASDAQ: NBSE) from Outperform to Sector Perform with a price target of $1.00 (from $12.00).
The analyst comments "On Friday, NBSE announced a major restructuring as part of a cost-saving measure and we... More
NeuBase Therapeutics (NBSE) Announces Strategic Restructuring Focused on Advancing Its Platform in Gene Editing
October 14, 2022 4:05 PM EDTNeuBase Therapeutics, Inc. (Nasdaq: NBSE) (NeuBase or the Company) today announced plans to restructure the Company to focus on the advancement of its platform in gene editing. Implementation of this strategy, which follows a strategic internal review by the Companys board of directors and management team, includes several initiatives aimed at streamlining the organization, reducing operating expenses, preserving capital, and creating long-term shareholder value.
After careful consideration of the current development timelines for our pipeline in conjunction with the tightening of the capital markets for small biotech companies over the past year,... More
